Latest Oncology News

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC

October 22nd 2021

Kristi Rosa

The frontline combination of trifluridine/tipiracil and bevacizumab was not found to result in a significant improvement in progression-free survival over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial.

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC

October 22nd 2021

Kristi Rosa

The European Commission has approved pembrolizumab plus chemotherapy for the frontline treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors have a PD-L1 expression combined positive score of 10 or higher and who have not previously received chemotherapy for metastatic disease.

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC

October 22nd 2021

Kristi Rosa

The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs

October 22nd 2021

The National Institutes of Health has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center.

Will Slow and Steady Progress in Treating SCLC Win the Race?

Will Slow and Steady Progress in Treating SCLC Win the Race?

October 22nd 2021

Christina T. Loguidice

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

Latest Oncology Videos

All Oncology News

Dr. Spaggiari on Surgical Interventions in CRC With Liver Metastases

October 7th 2021

Mario Spaggiari, MD

Mario Spaggiari, MD, discusses surgical interventions in colorectal cancer with liver metastases.

Dr. Sborov on Supportive Care Approaches to Selinexor-Associated Toxicities in Multiple Myeloma

October 7th 2021

Douglas W. Sborov, MD, MS

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Dr. Secord on Treatment Considerations in Platinum-Sensitive Ovarian Cancer

October 7th 2021

Angeles Alvarez Secord, MD

Angeles A. Secord, MD, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.

Dr. Jamieson on Treatment Considerations in Myelofibrosis

October 7th 2021

Catriona Jamieson, MD, PhD, University of California San Diego

Catriona Jamieson, MD, PhD, discusses treatment considerations for patients with myelofibrosis.

Dr. Jain on Advances With Surgery and Systemic Therapy in CRC With Liver Metastases

October 7th 2021

Shikha Jain, MD

Shikha Jain, MD, FACP, discusses advances with surgical interventions and systemic therapies in colorectal cancer with liver metastases.

Dr. Hansen on the PFS Benefit With Ide-Cel in Relapsed/Refractory MM

October 7th 2021

Doris Hansen, MD

Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.

Immunotherapy, Second-Generation AR Antagonists Provide Expansive Utility Throughout Prostate Cancer

October 7th 2021

Caroline Seymour

Sumit K. Subudhi, MD, PhD, discusses the treatment of patients with nonmetastatic castration-resistant prostate cancer, as well as those with metastatic castration-naïve, hormone-sensitive, and castration-resistant prostate cancer.

Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer

October 7th 2021

OncLive Staff

Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.

Management Strategies Shift Across NSCLC, Small Cell Lung Cancer, and Mesothelioma

October 7th 2021

Jessica Hergert

As novel therapies, new treatment strategies, and ongoing clinical trials continue to steer the path forward in lung cancer, treatment patterns for patients with non–small cell lung cancer, small cell lung cancer, and mesothelioma are continuing to evolve.

Rapid Readouts: ODENZA trial

October 7th 2021

Tian Zhang, MD

Dr Zhang, MD, discusses cognitive assessment data from patients with metastatic castrate-resistant prostate cancer in the ODENZA trial receiving either darolutamide or enzalutamide that was presented at the European Society for Medical Oncology 2021 Annual Meeting.

MSH3 IHC and Tetranucleotide MSI Analysis Should Not Be Routine in CRC

October 7th 2021

Caroline Seymour

MSH3 immunohistochemistry and tetranucleotide analysis failed to demonstrate concordance in identifying microsatellite instability in a cohort of colorectal cancer cases at selected tetranucleotide repeats, suggesting that the dual assessment strategy is not ready for routine use in diagnostic workup.

Balancing the Risk and Benefit of Anticoagulation in Patients on BTKi

October 7th 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, review the risk versus benefit of anticoagulation strategies in patients on BTKi.

Baseline Testing Prior to Initiation of BTKi Treatment in CLL

October 7th 2021

Drs Lenneman and Awan discuss baseline testing before choosing a treatment strategy for battling chronic lymphocytic leukemia.

Key Safety Considerations

October 7th 2021

Two experts discuss key safety considerations when treating patients with chronic lymphocytic leukemia.

A Review of Treatment Options in CLL

October 7th 2021

Carrie Lenneman, MD, MSCI, and Farrukh Awan, MD, give an overview of chronic lymphocytic leukemia, the standard of care for treatment, and the current and emerging BTK inhibitors used to treat CLL.

See All News